US20190192480A1 - Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof - Google Patents

Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
US20190192480A1
US20190192480A1 US15/754,845 US201615754845A US2019192480A1 US 20190192480 A1 US20190192480 A1 US 20190192480A1 US 201615754845 A US201615754845 A US 201615754845A US 2019192480 A1 US2019192480 A1 US 2019192480A1
Authority
US
United States
Prior art keywords
cromolyn
liver
preventing
pharmaceutical composition
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/754,845
Other languages
English (en)
Inventor
Jin Woo Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncocross Co Ltd
Original Assignee
Oncocross Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncocross Co Ltd filed Critical Oncocross Co Ltd
Assigned to ONCOCROSS CO. LTD. reassignment ONCOCROSS CO. LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHOI, JIN WOO
Publication of US20190192480A1 publication Critical patent/US20190192480A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/14—Organic oxygen compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L23/00—Soups; Sauces; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating various liver diseases including liver cirrhosis, containing cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Liver fibrosis is the excessive accumulation of fibers in the liver that results from liver disorders, which could have been caused by acute damage such as damage to the liver cells due to hepatitis C or hepatitis B virus, alcohol, toxins, etc. Reversible wound-healing reactions against the damage reflect an important balance between liver repair and scar formation (see Reference Document No. 1). Chronic damage gradually replaces liver parenchyma to scar tissues, thereby eventually resulting in liver cirrhosis. Fibrosis is also relevant to excessive wound-healing reaction which is caused by the excessive accumulation of scar tissues such as extracellular matrix. When fibrosis spreads in the liver, liver cirrhosis is caused, and consequently, complications such as hepatic failure and hepatocellular carcinoma are caused which can lead to patient deaths.
  • Hepatic stellate cell is a type of cell which triggers diseases, and is an important contributor to liver cirrhosis development caused by various causes of diseases such as infection with the hepatitis virus and alcohol consumption (see Reference Document No. 2).
  • HSC Hepatic stellate cell
  • extracellular matrix components for example, collagen
  • Such series of events activate HSC again, thus forming a detrimental cycle which triggers the process of liver cirrhosis (hepatocirrhosis) (see Reference Document No. 3).
  • HSC proliferation and activation are mediated by various signaling (see Reference Document No.
  • HSC signaling inhibitors have the potential to be developed as antifibrotic agents they have been studied continuously.
  • the antifibrotic effects of several synthetic compounds and biological drugs relate to HSC proliferation-related growth factors and related signaling pathways which reduce the proliferative response of HSC (see Reference Document Nos. 5 and 6).
  • curcumin see Reference Document No. 7
  • a plant extract containing silymarin see Reference Document No. 8
  • Ginkgo biloba extract see Reference Document No. 9
  • Salvia extract see Reference Document No. 10
  • myofibroblasts have been reported to activate myofibroblasts, inhibit connective tissue growth factors accumulated in the liver (see Reference Document No. 11), and stimulate the release of the components of fiber formation, thus inhibiting the TGF- ⁇ pathway which contributes to the profibrogenic pathway (see Reference Document No. 12).
  • HSC epithelial mesenchymal transition
  • telomere shortening see Reference Document No. 15
  • HSC epithelial mesenchymal transition
  • a connectivity map is a noteworthy algorithm that is used for evaluating the chemical substance candidates which alter gene expression (see Reference Document Nos. 19 and 20).
  • the above pharmacological strategy is to identify a candidate substance which is expected to show high functionality in vivo and may make the drug development process more effective.
  • cromolyn is a compound which prevents the secretion of histamine and leukotriene from sensitized mast cells in the mucous membrane of the lung and eyes, and is known to indirectly prevent the calcium ions from entering the cells, even though its exact working mechanism is not known yet. Furthermore, cromolyn is known to inhibit secondary bronchospasm caused by tachykinin by inhibiting neural reflex in the lung, and is known to inhibit the migration of immunocytes such as neutrophils, monocytes, eosinophils, etc. and to downregulate the beta-2 functional groups of lymphocytes. However, its effect with respect to various liver diseases including liver cirrhosis is not known.
  • cromolyn which was selected by the connectivity map, inhibits the accumulation of collagen and the production of TGF- ⁇ , which are known as the major secretion marker of hepatic stellate cells (HSCs) and also suppresses hepatocyte migration caused by TGF- ⁇ . Further, cromolyn was found to inhibit the decrease of E-cadherin expression resulting from EMT progression and have an anti-senescence effect on hepatocytes.
  • the present invention was completed by finding that cromolyn has the dual effect of inhibiting the activity of HSCs and promoting the recovery of hepatocyte function, and thus is capable of being used as a fundamental therapeutic agent for liver cirrhosis.
  • Non-Patent Document 1 Mogler C, Wieland M, Konig C, et al. Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage. EMBO molecular medicine. 2015; 7: 332-8.
  • Non-Patent Document 2 [2] Huang G, Brigstock D R. Regulation of hepatic stellate cells by connective tissue growth factor. Frontiers in bioscience. 2012; 17: 2495-507.
  • Non-Patent Document 3 [3] Iredale J P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. The Journal of clinical investigation. 2007; 117: 539-48.
  • Non-Patent Document 4 [4] Friedman S L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiological reviews. 2008; 88: 125-72.
  • Non-Patent Document 5 Neef M, Ledermann M, Saegesser H, et al. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. Journal of hepatology. 2006; 44: 167-75.
  • Non-Patent Document 6 Patsenker E, Stickel F. Role of integrins in fibrosing liver diseases. American journal of physiology Gastrointestinal and liver physiology. 2011; 301: G425-34.
  • Non-Patent Document 7 Yao Q Y, Xu B L, Wang J Y, Liu H C, Zhang S C, Tu C T. Inhibition by curcumin of multiple sites of the transforming growth factor-betal signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC complementary and alternative medicine. 2012; 12: 156.
  • Non-Patent Document 8 [8] Tzeng J I, Chen M F, Chung H H, Cheng J T. Silymarin decreases connective tissue growth factor to improve liver fibrosis in rats treated with carbon tetrachloride. Phytotherapy research: PTR. 2013; 27: 1023-8.
  • Non-Patent Document 9 Zhang C, Zhu Y, Wan J, Xu H, Shi H, Lu X. Effects of Ginkgo biloba extract on cell proliferation, cytokines and extracellular matrix of hepatic stellate cells. Liver international: official journal of the International Association for the Study of the Liver. 2006; 26: 1283-90.
  • Non-Patent Document 10 Hsu Y C, Lin Y L, Chiu Y T, Shiao M S, Lee C Y, Huang Y T. Antifibrotic effects of Salvia miltiorrhiza on dimethylnitrosamine-intoxicated rats. Journal of biomedical science. 2005; 12: 185-95.
  • Non-Patent Document 11 [11] Gressner O A, Gressner A M. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver international : official journal of the International Association for the Study of the Liver. 2008; 28: 1065-79.
  • Non-Patent Document 12 [12] Mauviel A. Transforming growth factor-beta signaling in skin: stromal to epithelial cross-talk. The Journal of investigative dermatology. 2009; 129: 7-9.
  • Non-Patent Document 13 [13] Wen S L, Gao J H, Yang W J, et al. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes. Journal of gastroenterology and hepatology. 2014; 29: 1932-42.
  • Non-Patent Document 14 [14] Iwaisako K, Brenner D A, Kisseleva T. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. Journal of gastroenterology and hepatology. 2012; 27 Supp12: 65-8.
  • Non-Patent Document 15 [15] Wiemann S U, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2002; 16: 935-42.
  • Non-Patent Document 16 Giampieri M P, Jezequel A M, Orlandi F. The lipocytes in normal human liver. A quantitative study. Digestion. 1981; 22: 165-9.
  • Non-Patent Document 17 [17] Friedman S L, Rockey D C, McGuire R F, Maher J J, Boyles J K, Yamasaki G. Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology. 1992; 15: 234-43.
  • Non-Patent Document 18 [18] Blakey J D, Hall I P. Current progress in pharmacogenetics. British journal of clinical pharmacology. 2011; 71: 824-31.
  • Non-Patent Document 19 [19] Lamb J, Crawford E D, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006; 313: 1929-35.
  • Non-Patent Document 20 [20] Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer cell. 2006; 10: 331-42.
  • Non-Patent Document 21 Huettner J E, Bean B P. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels. Proceedings of the National Academy of Sciences of the United States of America. 1988; 85: 1307-11.
  • Non-Patent Document 22 [22] Schmitt J K, Johns S B. Altering therapy of type II diabetes mellitus from insulin to tolazamide increases blood pressure in spite of weight loss. American journal of hypertension. 1995; 8: 520-3.
  • Non-Patent Document 23 [23] Renko K, Hoefig C S, Hiller F, Schomburg L, Kohrle J. Identification of iopanoic acid as substrate of type 1 deiodinase by a novel nonradioactive iodide-release assay. Endocrinology. 2012; 153: 2506-13.
  • Non-Patent Document 24 Bissell D M, Wang S S, Jarnagin W R, Roll F J. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. The Journal of clinical investigation. 1995; 96: 447-55.
  • Non-Patent Document 25 [25] Schuppan D, Kim Y O. Evolving therapies for liver fibrosis. The Journal of clinical investigation. 2013; 123: 1887-901.
  • Non-Patent Document 26 Kanellakis P, Ditiatkovski M, Kostolias G, Bobik A. A pro-fibrotic role for interleukin-4 in cardiac pressure overload. Cardiovascular research. 2012; 95: 77-85.
  • Non-Patent Document 27 Veerappan A, O'Connor N J, Brazin J, et al. Mast cells: a pivotal role in pulmonary fibrosis. DNA and cell biology. 2013; 32: 206-18.
  • Non-Patent Document 28 [28] Henz B M. Exploring the mast cell enigma: a personal reflection of what remains to be done. Experimental dermatology. 2008; 17: 91-9.
  • Non-Patent Document 29 Amiot L, Vu N, Rauch M, et al. Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis. Journal of hepatology. 2014; 60: 245-52.
  • Non-Patent Document 30 [30] Ishii M, Iwai M, Harada Y, et al. A role of mast cells for hepatic fibrosis in primary sclerosing cholangitis. Hepatology research: the official journal of the Japan Society of Hepatology. 2005; 31: 127-31.
  • Non-Patent Document 31 Jeong D H, Lee G P, Jeong W I, et al. Alterations of mast cells and TGF-betal on the silymarin treatment for CC1(4)-induced hepatic fibrosis. World journal of gastroenterology: WJG. 2005; 11: 1141-8.
  • Non-Patent Document 32 (Non-Patent Document 32) [32] Jin Y L, Zhou Q, Tian C, Liu H G, Hayashi Y, Enzan H. [Effects of mast cells on degradation of collagen fibers in dimethylnitrosamine-induced hepatic fibrosis of rat]. Zhonghua bing li xue za zhi Chinese journal of pathology. 2012; 41: 260-4.
  • Non-Patent Document 33 [33] Amiot L, Vu N, Samson M. Biology of the immunomodulatory molecule HLA-G in human liver diseases. Journal of hepatology. 2015.
  • Non-Patent Document 34 [34] Fend F, Raffeld M. Laser capture microdissection in pathology. Journal of clinical pathology. 2000; 53: 666-72.
  • Non-Patent Document 35 Kim T, Lim C S, Kaang B K. Cell type-specific gene expression profiling in brain tissue: Comparison among TRAP, LCM and RNA-seq. BMB reports. 2015.
  • the object of the present invention relates to a pharmaceutical composition and health food for preventing and treating liver diseases comprising cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing and treating liver diseases comprising cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides health food for preventing and ameliorating liver diseases comprising cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the cromolyn of the present invention or its pharmaceutically acceptable salt inhibits the accumulation of collagen and the production of TGF- ⁇ , which are known as the major secretion marker of hepatic stellate cells (HSCs), and also suppresses hepatocyte migration caused by TGF- ⁇ . Further, it inhibits the decrease of E-cadherin expression resulting from EMT progression and has an anti-senescence effect on hepatocytes. As a result, cromolyn has the dual effect of inhibiting the activity of HSCs and promoting the recovery of hepatocyte function, and thus can be used as a fundamental therapeutic agent for various liver diseases including liver cirrhosis.
  • TGF- ⁇ which are known as the major secretion marker of hepatic stellate cells (HSCs)
  • HSCs hepatic stellate cells
  • FIG. 1 depicts a method for identifying an anti-liver cirrhosis candidate agent using the connectivity map.
  • FIG. 2 verifies the effects on the proliferation and cytotoxicity of hepatic stellate cell (HSC) by using the candidate agent of the present invention
  • HSC-T6 cell line was treated with the untreated control, cromolyn, and ionomycin, respectively, and then the effects on cell proliferation were confirmed by MTT assay;
  • LX-2 cell line was treated with the untreated control, cromolyn, and ionomycin, respectively, and then the effects on cell proliferation were confirmed by MTT assay;
  • HSC-T6 cell line was treated with cromolyn and ionomycin, respectively, in different concentrations, and then the effects on cytotoxicity were confirmed by LDH assay;
  • LX-2 cell line was treated with cromolyn and ionomycin, respectively, in different concentrations, and then the effects on cytotoxicity were confirmed by LDH assay.
  • FIG. 3 verifies the changes in the levels of secreted collagen and TGF- ⁇ of hepatic stellate cell line after treatment with cromolyn:
  • A shows the relative amount of collagen in the HSC-T6 and LX-2 cell lines after treating with cromolyn in different concentrations
  • TGF- ⁇ shows the relative amount of TGF- ⁇ in the HSC-T6 and LX-2 cell lines after treating with cromolyn in different concentrations.
  • FIG. 4 verifies the inhibitory effects on EMP (epithelial mesenchymal transition) induced by TGF- ⁇ by the treatment with cromolyn in hepatocytes:
  • A verifies the effects of cromolyn on cell motility at 0 and 48 hours after treating with cromolyn, with or without TGF- ⁇ (2 ng/mL) through the wound analysis using a microscope (Scale bar: 100 ⁇ m);
  • FIG. 5 verifies the effect of cromolyn on the production of ⁇ -galactosidase:
  • A verifies the anti-senescence effect through ⁇ -galactosidase staining after treating with cromolyn;
  • the present invention provides a pharmaceutical composition for preventing and treating liver diseases comprising cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the cromolyn is a compound represented as [Formula 1] below.
  • the cromolyn inhibits the activity of hepatic stellate cell (HSC) and promotes the recovery of hepatocyte function; more preferably, the inhibition of HSC activity inhibits the accumulation of collagen and the production of TGF- ⁇ in HSCs; and more preferably the recovery of hepatocyte function is that the cromolyn shows a significant inhibition of the decrease in E-cadherin expression caused by EMT progression in hepatocytes and anti-senescence effect on hepatocytes, but are not limited to the above.
  • HSC hepatic stellate cell
  • the liver diseases are preferably selected from the group consisting of liver cirrhosis, liver fibrosis, liver failure, liver cancer, and hepatitis, and more preferably are liver cirrhosis, liver fibrosis, and liver failure.
  • the present inventors primarily selected the anti-liver cirrhosis candidate agents by using the connectivity map (see Table 1 and FIG. 1 ), and then selected cromolyn and ionomycin in consideration of the side effects for the second time.
  • the present inventors selected cromolyn as the final candidate agent through confirmation of the effect on cytotoxicity with respect to HSCs since ionomycin has the possibility of cytotoxicity (see FIG. 2 ).
  • cromolyn inhibits the accumulation of collagen and the production of TGF- ⁇ , which are known as the major secretion marker of activated HSCs. As a result, they found that cromolyn reduces the accumulation of collagen and inhibits the production of TGF- ⁇ in a concentration-dependent manner (see FIG. 3 ).
  • the present inventors confirmed the inhibitory effect of cromolyn on hepatocyte EMT (epithelial-mesenchymal transition). As a result, they found that cromolyn effectively inhibits the migration activity of hepatocytes and significantly inhibits the decrease in E-cadherin expression (see FIG. 4 ).
  • the present inventors confirmed the anti-senescence effect of cromolyn on hepatocytes, and found that cromolyn has a significant anti-senescence effect on hepatocytes (see FIG. 5 ).
  • the cromolyn of the present invention not only inhibits the production of TGF- ⁇ and the accumulation of collagen, which are known as the major secretion marker of HSCs, but also inhibits hepatocyte migration caused by the treatment of hepatocytes with TGF- ⁇ inhibits the decrease in E-cadherin espression caused by EMT progression, and shows an anti-senescence effect on hepatocytes, thereby showing the dual effect of inhibiting the activity of HSCs as well as promoting the recovery of hepatocyte function. Therefore, the cromolyn of the present invention can be used as a fundamental pharmaceutical composition for treating various liver diseases including liver cirrhosis.
  • the present invention includes not only the cromolyn represented by Formula 1, but also all of its pharmaceutically acceptable salts and solvates, hydrates, racemates, or stereoisomers which can be manufactured therefrom.
  • the cromolyn of the present invention that is represented by Formula 1 can be used in the form of a pharmaceutically acceptable salt, and as the salt, the acid addition salts formed by a pharmaceutically acceptable free acid are useful.
  • the acid addition salts are obtained from mineral acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, and nontoxic organic acids such as aliphatic mono and dicarboxylate, phenyl-substituted alkanoate, hydroxyl alkanoate and alkandioate, aromatic acids, aliphatic and aromatic sulfonic acid.
  • Such pharmaceutically non-toxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitro benzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluene sulfonate
  • the acid addition salt according to the present invention can be prepared by common methods, for example, by dissolving the cromolyn represented by Formula 1 in an excess amount of acid solution, and precipitating the above salt by using a water-compatible organic solvent, for instance, methanol, ethanol, acetone or acetonitrile. Further, it can be prepared by drying through evaporating the solvent or the excess amount of acid in the mixture or conducting suction filtration of the precipitated salt.
  • a water-compatible organic solvent for instance, methanol, ethanol, acetone or acetonitrile.
  • a pharmaceutically acceptable metallic salt can be prepared by using a base.
  • salts of alkali metal or alkaline earth metal are obtained by dissolving a compound in an excess amount of the solution of alkali metal hydrides or alkaline earth metal hydrides, filtering the salt of the non-soluble compound, and evaporating and drying the residual solution.
  • a sodium, potassium, or calcium salt is obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate negative salt (e.g., silver nitrate).
  • the formulation is prepared by using a commonly-used filler, extender, binding agent, wetting agent, disintegrating agent, diluent such as surfactant, etc. or excipient.
  • a solid preparation for oral administration includes a tablet, pill, powder, granule, capsule, troche, etc., and such a solid preparation is prepared by mixing cromolyn represented by Formula 1 with at least one excipient, for example, starch, calcium carbonate, sucrose or lactose or gelatin, etc. Further, lubricants other than a simple excipient, such as magnesium stearate, talc are also used.
  • a liquid preparation for oral administration includes a suspension, a liquid preparation for internal use, emulsion, or syrup, etc., and various excipients other than water and liquid paraffin, which are simple diluents, such as a wetting agent, sweetening agent, flavoring agent, preservative, etc. can be included.
  • a sterilized solution In the parenteral preparation, a sterilized solution, non-aqueous solution, suspension solution, emulsion, lyophilized preparation, suppository preparation, etc. are included.
  • propylene glycol polyethylene glycol
  • vegetable oils such as olive oil
  • injectable esters such as ethyl oleate, etc.
  • Witepsol, Macrogol, Tween 61, cacao butter, laurinum, glycerol, gelatin, etc. can be used as substrates for the suppository preparation.
  • composition according to the present invention is administered in a pharmaceutically effective amount.
  • a pharmaceutically effective amount indicates an amount sufficient to treat the disease with a reasonable benefit/risk ratio that can be applied to medical treatment, and the level of effective dose can be determined depending on factors including the type of disease, severity of symptoms, activity of the drug, sensitivity to the drug, administration time, administration route and excretion ratio, treatment period, concurrently used drugs, and other factors that are well known in the medical field.
  • the composition of the present invention can be administered individually as a single drug or co-administered with other drugs; can be administered subsequently or concurrently with the conventional drugs; and can be administered in a single dose or multiple doses. It is important to administer the minimum amount that can achieve the maximum effect without the side effects considering all of the above factors, and this can be easily determined by a person skilled in the art.
  • the effective dose of the compound according to the present invention may vary depending on the age, gender, weight of the patient, and generally, it can be administered 0.1 mg-100 mg per 1 kg of weight, preferably 0.5 mg-10 mg daily or every other day, or administered once, twice, or three times per day.
  • the effective dose can be increased or decreased depending on the administration route, severity of obesity, gender, weight, age, etc., and thus, the above dose does not limit the scope of the present invention in any way.
  • the present invention provides health food for preventing or ameliorating liver diseases, which comprises cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the cromolyn of the present invention inhibits not only the production of TGF- ⁇ and the accumulation of collagen, which is known as the major secretion marker of hepatic stellate cells, but also hepatocyte migration caused by the treatment of hepatocytes with TGF- ⁇ and decrease in E-cadherin expression caused by EMT progression. Further, it has an anti-senescence effect on hepatocytes. From the above, cromolyn has the dual effect of inhibiting the activity of HSCs and promoting the recovery of hepatocyte function, and thus can be used as health food for preventing and ameliorating various liver diseases.
  • cromolyn of the present invention there is no limitation to the type of food to which the cromolyn of the present invention is added.
  • foods to which the cromolyn can be added are drinks, meat, sausage, bread, biscuit, rice cake, chocolate, candy, snacks, confectioneries, pizza, ramen, other noodles, gums, dairy products including ice cream, all sorts of soup, beverages, alcoholic beverages and vitamin complex, dairy products and processed dairy products, etc. and include all health foods which fall under the general definition.
  • the cromolyn of the present invention can be added to food as is or can be used together with other foods or food ingredients, and can be appropriately used according to the conventional methods.
  • the mixed amount of active ingredients can be properly determined depending on the purpose of use (prevention or amelioration).
  • the amount of the above compound added to health foods can be 0.1-90 parts by weight.
  • the above amount could be below the above range, and could be used in excess of the above range since there are no safety issues.
  • the composition for health food according to the present invention is a composition for a beverage
  • the ingredient other than containing the above compound as an essential component at the designated ratio there is no specific limitation to the ingredient other than containing the above compound as an essential component at the designated ratio.
  • the composition may contain various flavors or natural carbohydrates, etc. as additional ingredients, like conventional beverages.
  • the natural carbohydrates can be common saccharides such as monosaccharides (e.g., glucose, fructose, etc.); disaccharides (e.g., maltose, sucrose, etc.); and polysaccharides (e.g., dextrin, cyclodextrin, etc.), and glucose alcohol such as xylitol, sorbitol, erythritol, etc.
  • natural flavors thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as a flavor.
  • the ratio of natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 10 g, per 100 of the composition of the present invention.
  • the health food composition according to the present invention can contain various nutritional supplements, vitamins, minerals (electrolytes), flavors such as synthetic flavor and natural flavor, coloring agents and appetizers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salt, organic acids, protective colloid, which is a viscosity agent, pH regulator, stabilizer, preservative, glycerin, alcohol, carbonation agent used in soft drinks, etc.
  • the composition can contain flesh for the preparation of natural fruit juice and fruit juice and vegetable drink.
  • the above ingredients can be used individually or in a combination.
  • the proportion of the additives is not limited, but is generally selected from 0.1 to about 20 parts by weight per 100 parts by weight of the cromolyn of the present invention.
  • the experiment was performed by using the LX-2 and HCT-T6 cell lines provided by Professor Sang-Hyun Seung's research team (Seoul National University) and S. L. Friedman's research team (School of Medicine at Mount Sinai, USA), respectively, as the hepatic stellate cells (HSC) of the present invention. Specifically, the experiment was conducted by growing the cells at 37° C. and 5% CO 2 in DMEM (Dulbecco's Modified Eagle Medium) to which 10% of heat inactivated fetal bovine serum and 1% of penicillin and streptomycin were added.
  • DMEM Dynamic fetal bovine serum
  • the experiment on hepatocytes was conducted by isolating the primary hepatocyte from the liver of a male C57BL6 mouse of around 6 weeks old.
  • ionomycin and cromolyn were purchased from Cayman Chemical Company (Ann Arbor, USA) and Santa Cruz Biotechnology (Santa Cruz, USA), respectively, and they were used after dissolving in DMSO (dimethylsulfoxide) for the in vitro experiments.
  • GEO data was used to confirm the therapeutic signature of liver fibrosis or liver cirrhosis based on the gene expression profile.
  • the microarray data of the liver samples of liver cirrhosis from 40 patients and normal liver samples from 6 people from GSE25097 were used.
  • probe ID of which the intensity was changed 2.5 times or more was extracted.
  • the probe ID was combined to the gene symbols.
  • upregulated genes (710 genes) or downregulated genes (225 genes) were separated from the 2,226 gene symbols to which the above probe ID was combined by applying ‘logFC>
  • each gene symbol of the two separated groups was converted into probe ID corresponding to analytical Affymetrix HG U133A.
  • the connectivity map was performed by using the method disclosed in Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006; 313: 1929-35.
  • cromoglicic acid cromolyn; CID 2882
  • MK-801 Dizocilpine; CID 180081
  • iopanoic acid CID 3735
  • ionomycin CID 6912226
  • tolazamide CID 5503
  • MK-801 is a non-competitive antagonist of the glutamate receptor
  • tolazamide is used by patients suffering from type II diabetes by controlling glucose
  • iopanoic acid was developed to inhibit early deiodinase enzymes.
  • MK-801, tolazamide, and iopanoic acid were prohibited from being used for treatment due to their side effects in USA, and have the potential to cause side effects to patients suffering from liver cirrhosis. Therefore, in the present invention, the following experiments were conducted using cromolyn and ionomycin.
  • a MTT (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed, and the HSC-T6 and LX2 cell lines obtained from ⁇ Example 1> above were used as hepatic stellate cells.
  • the MTT assay was performed by seeding the cell suspensions of each cell onto a 96-well plate at a density of 5 ⁇ 10 4 cells/well. Then, the MTT stock solution (5 mg/mL) in which MTT was dissolved in PBS (phosphate-buffered saline, pH 7.2) was prepared, and 15 ⁇ L of the MTT solution was added to each well after filtration. After culturing for 4 hours at 37° C. and 5% CO 2 , the reaction was terminated by adding 185 ⁇ L of solubilization solution to each well, and then the cell viability was measured at an absorbance of 620 nm using an ELISA (enzyme-linked immunosorbent assay) reader. Furthermore, cell viability was measured by calculating the ratio of absorbance of the cells treated/untreated with the candidate agents.
  • PBS phosphate-buffered saline, pH 7.2
  • the amount of LDH released into the above culture medium was measured, and the experiment was conducted by using a LDH cytotoxicity assay kit (Cayman Chemical, USA) according to the method provided by the manufacturer.
  • DMEM Dulbecco's Modified Eagle Medium
  • penicillin and streptomycin were added, at 37° C. and 5% CO 2 .
  • the above cells were seeded in a 96-well plate at a density of 2 ⁇ 10 4 /well. Cromolyn and ionomycin were added thereto in increasing amounts.
  • cromolyn showed no cytotoxicity except at the high level (10 ⁇ M), while ionomycin was confirmed to induce cell death in a concentration dependent manner.
  • the present invention selected cromolyn as the final candidate and conducted the following experiments.
  • LX-2 and HCT-T6 cell lines were analyzed by ELISA.
  • collagen was detected by using the Sirius Red Total Collagen Detection Kit (Chondrex, USA).
  • the suspended cells were seeded in a 24-well plate at a density of 1 ⁇ 10 4 cells/well, and treated with various amounts of cromolyn for 48 hours. Then, the diluted solutions or standard samples were added to 1.5-mL centrifuge tubes in duplicate. Subsequently, each tube was incubated for 20 minutes at room temperature together with 500 ⁇ L of the Sirius Red solution. The supernatant was removed, the tubes were washed twice, and 200 ⁇ L of the final supernatant was transferred to a 96-well plate. The optical density was measured at 510-550 nm.
  • FIGS. 3A and 3B As a result, as shown in FIGS. 3A and 3B , as the level of cromolyn increases, the released collagen significantly decreases. Further, through ELISA, cromolyn was confirmed to inhibit the production of TGF- ⁇ in a concentration-dependent manner ( FIGS. 3A and B).
  • liver fibrosis goes through the EMT process (Iwaisako K, Brenner D A, Kisseleva T. What's new in liver fibrosis. The origin of myofibroblasts in liver fibrosis. Journal of gastroenterology and hepatology. 2012; 27 Suppl2: 65-8; Wiemann S U, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2002; 16: 935-42). Therefore, the present inventors confirmed the motility of primary hepatocytes by treating cromolyn in the presence and absence of TGF- ⁇ which induces EMT.
  • cell motility according to treatment with cromolyn was analyzed by using the known wound assay in the presence and absence of TGF- ⁇ (2 ng/mL), and the healing distance of the wound was measured by a LDH assay. Further, after treating with TGF- ⁇ and cromolyn, changes in the E-cadherin expression was verified, which was confirmed by treating primary hepatocytes with TGF- ⁇ (Carl Bio Chem, USA) and then conducting Western Blots using the antibody against E-cadherin (H-180) (Santa Cruz, USA). In addition, tubulin was used as the loading control.
  • SA- ⁇ -gal (Senescence ⁇ -galactosidase) staining was performed by using the Senescence ⁇ -Galactosidase Staining Kit (Biovision, USA) according to the method provided by the manufacturer. Specifically, after washing with PBS, the cells were fixed by 2% formaldehyde and 0.2% glutaraldehyde in PBS for 15 minutes at room temperature. The fixed cells were washed with PBS, and incubated together with X-gal staining solution for 24 hours at 37° C. The cells were visualized, and photographs were taken with the Zeiss PALM laser capture microdissection microscope (Zeiss, Germany)
  • FIG. 5 As a result, as shown in FIG. 5 , three days after culturing hepatocytes in vitro, the number of ⁇ -galactosidase-positive cells increased considerably, but by the cromolyn treatment, the number of ⁇ -galactosidase-positive cells were found to decrease in a concentration-dependent manner ( FIGS. 5 A and B).
  • the powder was prepared by pulverizing and mixing the above ingredients, and then filling them into sealed sachets.
  • tablets were prepared by mixing the above ingredients, and then tableting the mixture.
  • capsules were prepared by mixing the above ingredients, and then filling the mixture into gelatin capsules.
  • the granules were prepared by adding 100 mL of 30% ethanol to the mixture, forming granules by drying at 60, and then filling into sachets.
  • the pills were prepared to contain 4 g per 1 pill according to the general preparation methods for pills.
  • the injection was prepared by mixing the above ingredients so that one ample contains 2 mL.
  • the liquid formulation was prepared by dissolving the above ingredients in purified water, adding a proper scent thereto, and then filling the resulting product in a bottle and sterilizing it.
  • cromolyn of the present invention 0.5-5.0 parts by weight was added to wheat flour and, by using the thus-obtained mixture, bread, cake, cookies, crackers, and noodles were prepared.
  • Ground beef for health was prepared by adding 10 parts by weight of the cromolyn of the present invention to ground beef.
  • Brown rice, barley, glutinous rice, and adlay were alpharized by a known method and dried.
  • the dried product was roasted and then prepared as powder having a particle size of 60 mesh by using a grinder.
  • black bean, black sesame, perilla seeds were steamed by a known method and dried.
  • the dried product was roasted and then prepared as powder having a particle size of 60 mesh by using a grinder.
  • the cromolyn of the present invention was concentrated at a low pressure by a vacuum evaporator, dried by a spray drying machine and hot-air drying machine.
  • the thus-obtained dried product was pulverized into a particle size of 60 mesh by a grinder, thereby obtaining the dried powder.
  • the sunsik (powder made of mixed grains) was prepared by mixing grains, seeds and nuts prepared in the above, and the cromolyn of the present invention in the following ratio:
  • the supplementary ingredients such as high fructose corn syrup (0.5%), oligosaccharide (2%), sugar (2%), saline solution (0.5%), and water (75%) were homogeneously mixed with 5 g of the cromolyn of the present invention.
  • the health beverage was prepared by packaging in a small packaging container such as a glass bottle, plastic bottle, etc.
  • Vegetable juice was prepared by adding 5 g of the cromolyn of the present invention to 1,000 mL of tomato or carrot juice.
  • Fruit juice was prepared by adding 1 g of the cromolyn of the present invention to 1,000 mL of apple or grape juice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seeds, Soups, And Other Foods (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Confectionery (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Noodles (AREA)
  • Dairy Products (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
US15/754,845 2015-08-28 2016-08-24 Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof Abandoned US20190192480A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150122138A KR101694753B1 (ko) 2015-08-28 2015-08-28 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 간질환 예방 및 치료용 약학적 조성물
KR10-2015-0122138 2015-08-28
PCT/KR2016/009368 WO2017039215A1 (ko) 2015-08-28 2016-08-24 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 간질환 예방 및 치료용 약학적 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/009368 A-371-Of-International WO2017039215A1 (ko) 2015-08-28 2016-08-24 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 간질환 예방 및 치료용 약학적 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/776,267 Division US11219613B2 (en) 2015-08-28 2020-01-29 Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof

Publications (1)

Publication Number Publication Date
US20190192480A1 true US20190192480A1 (en) 2019-06-27

Family

ID=57832906

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/754,845 Abandoned US20190192480A1 (en) 2015-08-28 2016-08-24 Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof
US16/776,267 Active 2037-02-05 US11219613B2 (en) 2015-08-28 2020-01-29 Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/776,267 Active 2037-02-05 US11219613B2 (en) 2015-08-28 2020-01-29 Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof

Country Status (13)

Country Link
US (2) US20190192480A1 (ja)
EP (1) EP3342408A4 (ja)
JP (2) JP2018531282A (ja)
KR (1) KR101694753B1 (ja)
CN (1) CN108348499A (ja)
AU (1) AU2016316408B2 (ja)
CA (1) CA2996494A1 (ja)
HK (1) HK1251988A1 (ja)
PH (1) PH12018500384A1 (ja)
RU (1) RU2018110607A (ja)
SG (1) SG11201801423PA (ja)
WO (1) WO2017039215A1 (ja)
ZA (1) ZA201801839B (ja)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252807B2 (en) * 2007-03-02 2012-08-28 Board Of Regents, The University Of Texas System Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2338745C1 (ru) 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
KR101218926B1 (ko) * 2007-08-22 2013-01-04 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
MX2012011629A (es) * 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
US20160023826A1 (en) 2013-03-15 2016-01-28 Wikifoods, Inc. Enclosing materials in natural transport systems
SI3104853T1 (sl) * 2014-02-10 2020-03-31 Respivant Sciences Gmbh Zdravljenje s stabilizatorji mastocitov za sistemske motnje

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252807B2 (en) * 2007-03-02 2012-08-28 Board Of Regents, The University Of Texas System Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products

Also Published As

Publication number Publication date
AU2016316408B2 (en) 2018-12-06
EP3342408A1 (en) 2018-07-04
SG11201801423PA (en) 2018-03-28
ZA201801839B (en) 2020-09-30
KR101694753B1 (ko) 2017-01-11
RU2018110607A (ru) 2019-09-30
WO2017039215A1 (ko) 2017-03-09
US11219613B2 (en) 2022-01-11
US20200345688A1 (en) 2020-11-05
AU2016316408A1 (en) 2018-04-26
JP2020007364A (ja) 2020-01-16
PH12018500384A1 (en) 2018-08-29
HK1251988A1 (zh) 2019-05-10
EP3342408A4 (en) 2019-04-24
JP2018531282A (ja) 2018-10-25
CA2996494A1 (en) 2017-03-09
CN108348499A (zh) 2018-07-31
RU2018110607A3 (ja) 2019-09-30

Similar Documents

Publication Publication Date Title
US10624938B2 (en) Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof
KR101855423B1 (ko) 인디루빈 유도체를 유효성분으로 포함하는 약학 조성물
CN103142720A (zh) 黑树莓提取物在制备抗糖尿病药物中的应用
KR101269208B1 (ko) 사우치논을 유효성분으로 포함하는 인슐린 저항성의 예방 또는 치료용 조성물
JP2008222656A (ja) 肥満改善および予防用組成物ならびに健康食品
US20160074338A1 (en) Food composition for preventing obesity, pharmaceutical composition for treating obesity, and animal medicine for treating obesity, containing gingernone a
US10507224B2 (en) Composition including kirenol or siegesbeckia herba extract for muscle function improvement or exercise ability enhancement
WO2018133563A1 (zh) 一种人参属植物提取物及其药物组合物和应用
CN102731597B (zh) 黄蜀葵花提取物及其化学成分的用途
KR20160123130A (ko) 감국 추출물 또는 분획물을 유효성분으로 포함하는 비만, 비만 관련 질환 또는 합병증의 예방, 개선 또는 치료용 조성물
US11219613B2 (en) Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof
KR102348782B1 (ko) 대추나무 뿌리 추출물을 포함하는 신장 질환의 예방 또는 치료용 조성물
KR101732146B1 (ko) 옥수수수염 및 탱자 복합추출물을 함유하는 항비만용 조성물
US20090318552A1 (en) Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizo dor treating or preventing diabetes mellitus and the use thereof
KR101332074B1 (ko) 에스큘레틴을 유효성분으로 함유하는 골 손실 억제용 조성물
KR20220132349A (ko) 신품종 고춧잎 추출물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
JP5985062B2 (ja) アルトカルプス・アルティリスの果実、葉、若しくは幹の抽出物、又はそれらの画分を有効成分として含有するがんの予防又は治療のための組成物
JP2018531282A6 (ja) クロモリンまたはこれの薬学的に許容可能な塩を有効成分として含有する肝疾患の予防及び治療用薬学的組成物
US20090263521A1 (en) Composition for the treatment of cancers and inhibition of metastasis containing extracts or fractions of the magnolia obovata
KR102199537B1 (ko) 우도 땅콩 새싹 추출물을 포함하는 비만 또는 대사성 질환의 예방 또는 치료용 조성물
KR102561751B1 (ko) Blb301(블랙라즈베리 및 속단 복합추출물)을 포함하는 근육 질환의 예방, 치료 또는 개선용 조성물
KR20190015942A (ko) 골 질환 예방 또는 치료용 화합물 및 이의 용도
US20240115537A1 (en) Composition for preventing or treating breast cancer comprising compound derived from dendropanax morbiferus
KR101219185B1 (ko) 신규 바이페닐 화합물 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 합병증의 예방 또는 치료용 약학적 조성물
KR102246783B1 (ko) Aralia excelsa 추출물 및 이의 분획물을 포함하는 항비만 및 항당뇨 예방 및 치료용 조성물

Legal Events

Date Code Title Description
AS Assignment

Owner name: ONCOCROSS CO. LTD., KOREA, DEMOCRATIC PEOPLE'S REP

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHOI, JIN WOO;REEL/FRAME:045019/0837

Effective date: 20180222

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION